for treatment of Retinitis Pigmentosa in Usher disease
A Phase 1 Clinical Trial of Nacuity’s GMP-grade NPI-001 solution in healthy volunteers was completed with acceptable results.
A randomized, placebo-controlled, double-masked, multicenter, Phase 1/2 Clinical Trial of Nacuity’s proprietary NPI-001 tablets, the SLO-RP Study, is enrolling patients with RP associated with Usher syndrome (NCT04355689).
This product has been granted orphan drug designation, so, an eligible new drug application would result in regulatory exclusivity for Nacuity.
NPI-002 Intravitreal Implant
for prevention or treatment of cataract
Nacuity has developed a prototype intravitreal implant loaded with a small antioxidant molecule, NPI-002. It is currently undergoing nonclinical testing as a prelude to a clinical trial.
NPI-001 Ophthalmic Insert
for the treatment of ocular effects of Cystinosis
Nacuity has developed a prototype ophthalmic insert containing a small molecule antioxidant for the treatment of ocular effects of cystinosis. In vivo nonclinical studies with the insert reveal that significant levels of drug can be delivered to the aqueous humor daily by wearing the ophthalmic insert under the eyelid. Nonclinical evaluation continues as a prelude to clinical studies. This product has been granted rare pediatric disease designation, so, an eligible new drug application would result in a priority review voucher for Nacuity.